Alira Health Welcomes Daniela Sica, Vice President, Business Development, Pharma and Biotech

News
Category:
Published on:
December 15, 2020

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Daniela Sica has joined the firm as Vice President, Business Development, Pharma and Biotech. Daniela has extensive experience in the pharmaceutical and biotech space, and is based out of Alira Health’s Barcelona, Spain office.

We are thrilled to welcome Daniela to the Alira Health Team,” said Benjamin Chambon, Chief Commercial Officer and EVP, Transaction Advisory. “Her notable experience in the pharma and biotech field will play a critical role in further enhancing the Alira Health lifecycle offering, and, in turn, continuing to improve synergies across our practice areas for the benefit of our clients.”
I have been following the evolution of Alira Health for several years, prior to joining the team,” said Daniela. “I have always admired the passion and commitment of the founders and leadership team, and the depth of expertise within the company. I am thrilled to join Alira Health at this exciting stage of its development.”

Daniela has over 25 years of management experience with pharmaceutical and biotech companies, and CDMOs. She has worked in business development, alliance management, and strategic planning with worldwide responsibilities, building a strong network of international relationships. Daniela has strong transaction experience, having led negotiations in co-development deals involving some of the largest global pharma companies.

Daniela sits on several biotech evaluation commissions, supporting biotech accelerators in their investment decisions. She has a degree in Food Science and Technology from the University of Milan, with a qualification as a Food Science Expert.

Learn more about our Team

Click here

Related news

News September 6, 2022
Alira Health Expands North American Capabilities with the Acquisition of Artisan Healthcare Consulting
The acquisition of Artisan strengthens and extends Alira Health’s Market Access and Management Consulting advisory practices in North America and globally.
Biotech Market Access Pharma Therapeutics
Publications August 25, 2022
Why—and When—to Use a CDMO
Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons. In this article, we explore(...)
CDMO Pharma Research and Development
Publications June 23, 2022
Developing Data Specialist Talent: Collaboration Is Key
Companies across Pharma and MedTech need talented people to cover the range of data-related challenges. Discover what this means for developing talent throughout the industry.
Data Specialist MedTech Pharma
News May 11, 2022
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
MedTech Patient Engagement Pharma
News April 5, 2022
Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia
We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)
Clinical MedTech Patient Engagement Pharma Regulatory Research & Development
Publications March 31, 2022
The FDA’s Project Orbis Can Speed up the Delivery of Your New Oncology Drug to Global Markets
Are you developing an oncology drug? Project Orbis, a program coordinated by the U.S. Food and Drug Administration (FDA), allows you to register your product in several countries with(...)
Pharma Regulatory
Events March 4, 2022
Bio Europe Spring 2022
Meet us at Bio Europe Spring 2022. Connect with us to learn how Alira Health can help accelerate innovation and deliver tomorrow’s standard of care.
Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.